BioCentury
ARTICLE | Clinical News

ISIP starts Phase III Crohn's trial

November 29, 2001 8:00 AM UTC

Isis (ISIP) began the first of 2 double-blind, placebo-controlled U.S. and Canadian Phase III trials of its alicaforsen ( ISIS 2302) to treat Crohn's disease. The trial will enroll up to 150 patients ...